PremiumCompany AnnouncementsPharma Mar SA Reports on Recent Share Buy-Back Activities PharmaMar Seeks EMA Approval for New Lung Cancer Treatment Pharma Mar SA Updates on Share Buy-Back Program PremiumCompany AnnouncementsPharmaMar Reports Strong Q1 2025 Financial Growth Pharma Mar Announces 2025 Shareholders Meeting with Key Governance Proposals Is PHMMF a Buy, Before Earnings? PremiumCompany AnnouncementsPharma Mar Implements Share Delivery Plan to Boost Employee Engagement Sylentis Secures 21.1 Million Euro Grant for RNA Drug Production PharmaMar Proposes 23% Dividend Increase Amid Strong Financial Performance